ALNYLAM PHARMACEUTICALS, INC. Capital Expenditures Incurred but Not yet Paid
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Capital Expenditures Incurred but Not yet Paid of $24.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $1.30M, a 17.95% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $5.52M.
- ALNYLAM PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $431.00K.
- ALNYLAM PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $3.65M, a 62.80% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $10.90M, a 369.10% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $2.32M, a 38.92% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $3.81M, a 27.01% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $5.21M, a 61.67% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.03M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $6.82M derived: sum of 2 quarters · filed 2026-02-12 | $7.25M derived: sum of 3 quarters · filed 2026-07-30 | $10.90M 10-K · filed 2026-02-12 |
| 2025-09-30 | $5.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $5.95M derived: sum of 2 quarters · filed 2026-07-30 | $9.60M 10-Q · filed 2025-10-30 | $11.19M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $431.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $4.08M 10-Q · filed 2026-07-30 | $5.66M derived: sum of 3 quarters · filed 2026-07-30 | $5.34M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $3.65M 10-Q · filed 2025-05-01 | $5.23M derived: sum of 2 quarters · filed 2026-02-12 | $4.91M derived: sum of 3 quarters · filed 2026-02-12 | $3.73M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.26M derived: sum of 2 quarters · filed 2026-02-12 | $82.00K derived: sum of 3 quarters · filed 2026-02-12 | $2.32M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$321.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$1.50M derived: sum of 2 quarters · filed 2025-10-30 | $742.00K 10-Q · filed 2025-10-30 | -$607.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $1.06M 10-Q · filed 2025-07-31 | -$286.00K derived: sum of 3 quarters · filed 2026-02-12 | -$795.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $2.24M 10-Q · filed 2025-05-01 | $893.00K derived: sum of 2 quarters · filed 2026-02-12 | $384.00K derived: sum of 3 quarters · filed 2026-02-12 | $2.01M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$1.86M derived: sum of 2 quarters · filed 2026-02-12 | -$229.00K derived: sum of 3 quarters · filed 2026-02-12 | $3.81M 10-K · filed 2026-02-12 |
| 2023-09-30 | -$509.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.12M derived: sum of 2 quarters · filed 2023-11-02 | $5.15M 10-Q · filed 2023-11-02 | $4.21M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $5.66M 10-Q · filed 2023-08-03 | $4.72M derived: sum of 3 quarters · filed 2025-02-13 | $4.36M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $4.03M 10-Q · filed 2023-05-04 | $3.09M derived: sum of 2 quarters · filed 2025-02-13 | $2.73M derived: sum of 3 quarters · filed 2025-02-13 | $929.00K derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | -$943.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$1.30M derived: sum of 2 quarters · filed 2025-02-13 | -$3.10M derived: sum of 3 quarters · filed 2025-02-13 | $5.21M 10-K · filed 2025-02-13 |
| 2022-09-30 | -$362.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$2.16M derived: sum of 2 quarters · filed 2023-11-02 | $6.16M 10-Q · filed 2023-11-02 | $10.34M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $6.52M 10-Q · filed 2023-08-03 | $10.70M derived: sum of 3 quarters · filed 2024-02-15 | $8.32M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $8.32M 10-Q · filed 2023-05-04 | $12.50M derived: sum of 2 quarters · filed 2024-02-15 | $10.12M derived: sum of 3 quarters · filed 2024-02-15 | $14.63M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.80M derived: sum of 2 quarters · filed 2024-02-15 | $6.31M derived: sum of 3 quarters · filed 2024-02-15 | $13.60M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $2.13M derived: sum of 2 quarters · filed 2022-07-28 | $9.41M 10-Q · filed 2021-10-28 | $16.88M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $4.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | $11.80M 10-Q · filed 2022-07-28 | $19.27M derived: sum of 3 quarters · filed 2023-02-23 | $19.91M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $7.29M 10-Q · filed 2022-04-28 | $14.76M derived: sum of 2 quarters · filed 2023-02-23 | $15.40M derived: sum of 3 quarters · filed 2023-02-23 | $15.19M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $7.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $8.12M derived: sum of 2 quarters · filed 2023-02-23 | $7.90M derived: sum of 3 quarters · filed 2023-02-23 | $14.52M 10-K · filed 2023-02-23 |
| 2020-09-30 | $646.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $429.00K derived: sum of 2 quarters · filed 2021-10-28 | $7.05M 10-Q · filed 2021-10-28 | $3.00M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | -$217.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $6.40M 10-Q · filed 2021-08-03 | $2.35M derived: sum of 3 quarters · filed 2022-02-10 | -$4.62M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $6.62M 10-Q · filed 2021-04-29 | $2.57M derived: sum of 2 quarters · filed 2022-02-10 | -$4.40M derived: sum of 3 quarters · filed 2022-02-10 | $8.46M derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | -$4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | -$11.02M derived: sum of 2 quarters · filed 2022-02-10 | $1.84M derived: sum of 3 quarters · filed 2022-02-10 | $14.88M 10-K · filed 2022-02-10 |
| 2019-09-30 | -$6.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $5.89M derived: sum of 2 quarters · filed 2020-11-05 | $18.92M 10-Q · filed 2020-11-05 | $32.46M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $12.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $25.89M 10-Q · filed 2020-08-06 | $39.43M derived: sum of 3 quarters · filed 2021-02-11 | $35.88M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $13.03M 10-Q · filed 2020-05-06 | $26.57M derived: sum of 2 quarters · filed 2021-02-11 | $23.02M derived: sum of 3 quarters · filed 2021-02-11 | $35.87M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $13.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $9.99M derived: sum of 2 quarters · filed 2021-02-11 | $22.84M derived: sum of 3 quarters · filed 2021-02-11 | $33.27M 10-K · filed 2021-02-11 |
| 2018-09-30 | -$3.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $9.30M derived: sum of 2 quarters · filed 2019-10-31 | $19.74M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $12.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $23.29M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $10.44M 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | $8.18M 10-K · filed 2020-02-13 | |||
| 2016-12-31 | $33.15M 10-K · filed 2019-02-14 | |||
| 2015-12-31 | $1.33M 10-K · filed 2018-02-15 | |||
| 2014-12-31 | $1.53M 10-K · filed 2017-02-15 | |||
| 2013-12-31 | $161.00K 10-K · filed 2016-02-12 | |||
| 2013-03-31 | $245.00K 10-Q · filed 2013-05-07 | |||
| 2012-12-31 | $1.44M 10-K · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |